

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 29,081,672

Date: 07/09/2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued development work on upgrades to its mobile apps and cloud-based platform to improve efficiency and accuracy and to add new feature sets (regarding its subsidiary Health Gauge). It also furthered its discussions with potential channel partners and other potential users of the HG technology.

Additionally, the Issuer achieved a listing on the Frankfurt Stock Exchange (under the symbol: 42FB), and established in new subsidiary, AI Rx Inc., to hold the exclusive North American commercial usage rights (USA, Canada, Mexico) to Tech2Health's complete portfolio of digital mental wellness and health-tech products and platform services, patents, technologies, brands and trademarks.

Finally, the Issuer continued contract work towards completion of a strategic partnership and equity interest in the Paris, France based company, Tech2Health, a company with a suite of products for the digital administration of mental health solutions.

2. Provide a general overview and discussion of the activities of management.

During the month, management has been primarily engaged in the improvement of Health Gauge's technology along with development of strategic partners arrangements and marketing plans for HG. Additionally, management was engaged in the conducting of due diligence regarding the acquisition of Tech2Health, along with contract preparation, and ongoing due diligence regarding other potential acquisitions.

Additionally, management worked with its auditors to complete and file the Issuer's audited Financial Statements for the year ended April 30, 2021.

3. Describe and provide details of any new products or services developed or offered.

None.

4. Describe and provide details of any products or services that were discontinued.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered an agreement with the Swiss based advisor, Pro Return AG to provide AIML with capital markets consulting services internationally. Pro Return shall focus on international markets with the goal of introductions to institutional investors in order to finance the Company, with consulting services to include a review of the Company's business plans, corporate presentations and general corporate development materials. The contract is set to run for a 17-month period commencing August 1, 2021 through December 31, 2022 at a cost of €23,530 per month. Pro Return AG is arms-length from AIML.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

The Issuer's advertising agreement with North Equities expired during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

The Issuer announced a warrant incentive program with the following terms:

The Company has 4,000,000 Series B Warrants outstanding, each entitling the holder to subscribe for one common share for \$0.50 until January 11, 2023. It also has 4,000,000 Series C Warrants outstanding, with each two (2) Series C Warrants allowing the acquisition of one common share for \$0.50 until January 11, 2022.

In order to induce the holders of the Series B and Series C Warrants to exercise their warrants early, the Company will issue one new warrant to such holders for each warrant exercised prior to September 30, 2021. This new warrant is exercisable at \$0.65 until January 11, 2023 for Series B holders, and each two new warrants are exercisable at \$0.65 until September 30, 2022 for Series C holders. All new warrants will be subject to the rights of the Company to accelerate

expiry upon 30 days' notice if the shares of the Company trade on the CSE at or above \$0.85 for a period of 10 days.

Insiders hold 12.5% of the Series B warrants and intend to exercise them early as part of this program. The Company is relying on various exemptions in MI 61-101 in respect to this insider participation.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.


There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance has been expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result and healthcare payors understand that the deployment of digital health solutions both improves outcomes and reduces costs. Governments across Europe are implementing laws requiring payors to cover the cost of digital mental health therapy to the same extent as conventional methods.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 07/09/2021.

Tim Daniels  
 Name of Director or Senior  
 Officer  
  
 Signature  
 Executive Chairman  
 Official Capacity

<b>Issuer Details</b>		For Month End	Date of Report
Name of Issuer		August 2021	YY/MM/D
AI/ML Innovations Inc.			21/09/07
Issuer Address			
Suite 203, 645 Fort St.			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Victoria, BC V8W 1G2			(778) 405-0882
Contact Name		Contact Position	Contact Telephone No.
Tim Daniels		Director	250 483-5650
Contact Email Address		Web Site Address	
tim.daniels@aiml-innovations.com		aiml-innovations.com	